BioNTech SE Sponsored ADR (BNTX) shares ended the last trading session 6.1% higher at $111.6. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the ...

BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the first quarter 2026 on Tuesday, May 5, 2026. Additionally, the Company will host a conference call ...

Trastuzumab pamirtecan, an investigational HER2-targeted antibody-drug conjugate, met the primary efficacy endpoint in a Phase 2 cohort of ...

The Phase II cohort analysis included 145 patients whose conditions had progressed following initial chemotherapy.

Trastuzumab pamirtecan, being developed under a 2023 partnership between BioNTech and DualityBio, elicited a 44.1% overall ...

Amid growing financial concerns and US vaccine hesitancy, the German company will close its mRNA site in Southeast Asia.

BioNTech’s fair value estimate has been trimmed from $139.51 to $131.39, a modest cut of about 6% that reflects the latest model inputs. This shift comes as analysts reassess the story around ...

New long-term clinical data for BioNTech's personalized mRNA cancer vaccine has delivered a potentially paradigm-shifting result in one of oncology's most challenging diseases. Presented at the ...

BioNTech SE (Nasdaq: BNTX, "BioNTech" or "the Company") will announce its financial results for the first quarter 2026 on Tuesday, May 5, 2026. Additionally ...